Status:

COMPLETED

Efficacy of Latanoprostene Bunod in Lowering Intraocular Pressure in Japanese Healthy Male Volunteers

Lead Sponsor:

Bausch & Lomb Incorporated

Conditions:

Intraocular Pressure

Eligibility:

MALE

20+ years

Phase:

PHASE1

Brief Summary

The objective of this study is to evaluate the effect of latanoprostene bunod dosed once daily (QD) in reducing intraocular pressure (IOP) measured over a 24-hour period in healthy subjects.

Eligibility Criteria

Inclusion

  • Participants with a corrected decimal visual acuity (VA) of 0.5 or better in both eyes.

Exclusion

  • Subjects with known hypersensitivity or contraindications to latanoprostene bunod, or any of the ingredients in the study drug.
  • Subjects with known contraindications to NO treatment.
  • Subjects who are unable to discontinue contact lens use at least 7 days prior to Visit 2 (Day 0/1/2) and during the 14 to 15-day study treatment period.
  • Subjects who are unable to discontinue the use of all topical ophthalmic medications, including artificial tears, at least 7 days prior to Visit 2 (Day 0/1/2) and during the 14 to 15-day study treatment period.
  • Subjects with any condition that prevents reliable applanation tonometry in either eye.
  • Subjects with glaucoma in either eye.
  • Subjects with any condition that prevents clear visualization of the fundus.
  • Subjects who are monocular.
  • Subjects with aphakia in either eye.
  • Subjects with an active corneal disease in either eye.
  • Subjects with severe dry eye in either eye.
  • Subjects with a history/diagnosis of a clinically significant or progressive retinal disease in either eye.
  • Subjects with any intraocular infection or inflammation within 3 months (90 days) prior to Visit 1 (Screening).
  • Subjects with a history of ocular laser surgery within the 3 months (90 days) prior to Visit 1 (Screening).
  • Subjects with a history of incisional ocular surgery or severe trauma.

Key Trial Info

Start Date :

July 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2013

Estimated Enrollment :

24 Patients enrolled

Trial Details

Trial ID

NCT01895985

Start Date

July 1 2013

End Date

October 1 2013

Last Update

May 15 2018

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Bausch & Lomb Incorporated

Madison, New Jersey, United States, 07940